Oncolytics Biotech Inc ONCY

RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway

[Noteable]

April 12, 2024 - " ..... a few key themes became apparent at the American Association for Cancer Research’s annual meeting [AACR24]. 

First and foremost, the programs presented are tackling difficult cancers with a high unmet need and a dire prognosis. Some of the presentations last weekend involved drug candidates targeting pancreatic cancer, for example. In 2023, the five-year survival rate for pancreatic cancer was just 12%, according to the American Cancer Society. 

Two presentations—one on Bristol Myers Squibb’s blockbuster immunotherapy Opdivo, the other on a messenger RNA vaccine in development by BioNTech and Genentech—showed promising signals. Opdivo’s trial, the first reported of a PD1 inhibitor in neoadjuvant pancreatic cancer, indicated that the drug may improve outcomes, while BioNTech and Genentech’s vaccine continued to show potential in a particularly difficult-to-treat form of the disease. 

This announcement also dovetailed with another prominent theme at AACR: the resurgence of cancer vaccines, which are also making inroads in advanced liver cancer, head and neck cancer, non-small cell lung cancer and glioblastoma. ... "

https://www.biospace.com/article/vaccines-next-gen-approaches-target-the-toughest-cancers-aacr/